Transversal psoas muscle thickness measurement is associated with response and survival in patients with HCC undergoing immunotherapy.
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
01 10 2023
01 10 2023
Historique:
received:
23
03
2023
accepted:
18
07
2023
medline:
18
9
2023
pubmed:
14
9
2023
entrez:
14
9
2023
Statut:
epublish
Résumé
Sarcopenia is a common problem in patients with HCC. We aimed to evaluate the prognostic and predictive value of baseline transversal psoas muscle thickness (TPMT) measurement in patients with HCC undergoing immunotherapy. HCC patients treated with programmed death ligand 1-based therapies between June 2016 and October 2022 at the Vienna General Hospital (n = 80) and the Hôpital Beaujon Clichy (n = 96) were included and followed until April 2023. TPMT at the level of the third lumbar vertebra was measured independently by 2 radiologists to evaluate interreader reliability. TPMT <12 mm/m in men and <8 mm/m in women indicated sarcopenia. Overall, 176 patients (age: 66.3±11.7 y; male: n=143, 81%, Barcelona-Clinic Liver Cancer C: n=121, 69%) were included, of which 131 (74%) exhibited cirrhosis. Interreader agreement for the diagnosis of sarcopenia based on TPMT was 92.6%, and Cohen κ showed a "strong agreement" [κ = 0.84 (95% CI: 0.75-0.92)]. Sarcopenia, present in 58 patients (33%), was associated with shorter median overall survival [7.2 (95% CI: 5.0-9.5) vs. 22.6 (95% CI: 16.4-28.8 months); p < 0.001] and median progression-free survival [3.4 (95% CI: 0.2-6.8) vs. 7.9 (95% CI: 5.8-9.9 months), p = 0.001], and an independent predictor of overall [adjusted HR: 1.63 (95% CI: 1.07-2.48)] and progression-free mortality [adjusted HR: 1.54 (95% CI: 1.06-2.23)] in multivariable analyses. The objective response rate [evaluable in 162 subjects (92.0%)] per modified Response Evaluation Criteria In Solid Tumors (mRECIST) in patients with and without sarcopenia was 22% and 39%, respectively (p = 0.029). Survival and radiological responses were worse in patients with sarcopenia and systemic inflammation [median overall survival: 6.1 (95% CI: 3.6-8.6) mo; median progression-free survival: 2.8 (95% CI: 2.1-3.4) mo; objective response rate=16%; disease control rate=39%]. Evaluation of sarcopenia using TPMT measurement is reliable and identifies HCC patients with a dismal prognosis and response to immunotherapy.
Sections du résumé
BACKGROUND
Sarcopenia is a common problem in patients with HCC. We aimed to evaluate the prognostic and predictive value of baseline transversal psoas muscle thickness (TPMT) measurement in patients with HCC undergoing immunotherapy.
METHODS
HCC patients treated with programmed death ligand 1-based therapies between June 2016 and October 2022 at the Vienna General Hospital (n = 80) and the Hôpital Beaujon Clichy (n = 96) were included and followed until April 2023. TPMT at the level of the third lumbar vertebra was measured independently by 2 radiologists to evaluate interreader reliability. TPMT <12 mm/m in men and <8 mm/m in women indicated sarcopenia.
RESULTS
Overall, 176 patients (age: 66.3±11.7 y; male: n=143, 81%, Barcelona-Clinic Liver Cancer C: n=121, 69%) were included, of which 131 (74%) exhibited cirrhosis. Interreader agreement for the diagnosis of sarcopenia based on TPMT was 92.6%, and Cohen κ showed a "strong agreement" [κ = 0.84 (95% CI: 0.75-0.92)]. Sarcopenia, present in 58 patients (33%), was associated with shorter median overall survival [7.2 (95% CI: 5.0-9.5) vs. 22.6 (95% CI: 16.4-28.8 months); p < 0.001] and median progression-free survival [3.4 (95% CI: 0.2-6.8) vs. 7.9 (95% CI: 5.8-9.9 months), p = 0.001], and an independent predictor of overall [adjusted HR: 1.63 (95% CI: 1.07-2.48)] and progression-free mortality [adjusted HR: 1.54 (95% CI: 1.06-2.23)] in multivariable analyses. The objective response rate [evaluable in 162 subjects (92.0%)] per modified Response Evaluation Criteria In Solid Tumors (mRECIST) in patients with and without sarcopenia was 22% and 39%, respectively (p = 0.029). Survival and radiological responses were worse in patients with sarcopenia and systemic inflammation [median overall survival: 6.1 (95% CI: 3.6-8.6) mo; median progression-free survival: 2.8 (95% CI: 2.1-3.4) mo; objective response rate=16%; disease control rate=39%].
CONCLUSIONS
Evaluation of sarcopenia using TPMT measurement is reliable and identifies HCC patients with a dismal prognosis and response to immunotherapy.
Identifiants
pubmed: 37708441
doi: 10.1097/HC9.0000000000000261
pii: 02009842-202310010-00013
pmc: PMC10503692
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Association for the Study of Liver Diseases.
Références
JAMA Oncol. 2021 Jan 01;7(1):113-123
pubmed: 33090190
Lancet Oncol. 2011 May;12(5):489-95
pubmed: 21296615
J Hepatol. 2021 Oct;75(4):960-974
pubmed: 34256065
Control Clin Trials. 1996 Aug;17(4):343-6
pubmed: 8889347
Hepatology. 2013 Jun;57(6):2224-34
pubmed: 22961713
Front Immunol. 2019 Sep 18;10:2183
pubmed: 31620123
Hepatology. 2019 Nov;70(5):1816-1829
pubmed: 31220351
Cancers (Basel). 2022 Jul 21;14(14):
pubmed: 35884610
World J Gastroenterol. 2022 Jan 28;28(4):432-448
pubmed: 35125828
Clin Gastroenterol Hepatol. 2012 Feb;10(2):166-73, 173.e1
pubmed: 21893129
Nature. 2008 Jul 24;454(7203):436-44
pubmed: 18650914
J Hepatol. 2017 Jun;66(6):1166-1172
pubmed: 28131794
Am J Clin Oncol. 2021 Feb 1;44(2):74-81
pubmed: 33350681
Am J Clin Oncol. 1982 Dec;5(6):649-55
pubmed: 7165009
Nat Rev Clin Oncol. 2018 Oct;15(10):599-616
pubmed: 30061739
Biochem Med (Zagreb). 2012;22(3):276-82
pubmed: 23092060
Front Nutr. 2022 Dec 14;9:978110
pubmed: 36590214
J Immunother Cancer. 2020 Apr;8(1):
pubmed: 32303612
J Cachexia Sarcopenia Muscle. 2021 Oct;12(5):1122-1135
pubmed: 34337889
Liver Int. 2019 Dec;39(12):2374-2385
pubmed: 31421002
J Hepatol. 2022 Feb;76(2):353-363
pubmed: 34648895
J Gerontol A Biol Sci Med Sci. 2003 Oct;58(10):M911-6
pubmed: 14570858
EBioMedicine. 2019 Nov;49:381-388
pubmed: 31662290
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Liver Int. 2021 Apr;41(4):799-809
pubmed: 33290614
Age Ageing. 2019 Jan 1;48(1):16-31
pubmed: 30312372
PLoS One. 2019 May 29;14(5):e0216677
pubmed: 31141535
Aliment Pharmacol Ther. 2016 Apr;43(7):765-77
pubmed: 26847265
Gut. 2021 Jan;70(1):204-214
pubmed: 32747413
J Hepatol. 2022 Mar;76(3):681-693
pubmed: 34801630
J Hepatol. 2018 Apr;68(4):707-714
pubmed: 29221886
Front Oncol. 2022 Apr 08;12:854096
pubmed: 35463384
Thorac Cancer. 2019 Feb;10(2):347-351
pubmed: 30600905
J Hepatol. 2020 Feb;72(2):288-306
pubmed: 31954493
N Engl J Med. 2020 May 14;382(20):1894-1905
pubmed: 32402160
J Clin Oncol. 2021 Jul 1;39(19):2068-2078
pubmed: 34043430
Eur Radiol. 2023 Jan;33(1):512-522
pubmed: 35864351
Therap Adv Gastroenterol. 2022 Dec 26;15:17562848221142417
pubmed: 36600683
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Liver Int. 2017 Jul;37(7):1047-1055
pubmed: 28066978
Lancet Oncol. 2008 Jul;9(7):629-35
pubmed: 18539529
Maturitas. 2017 Feb;96:10-15
pubmed: 28041587
Cancer Discov. 2022 Jan;12(1):31-46
pubmed: 35022204
Nat Rev Clin Oncol. 2013 Feb;10(2):90-9
pubmed: 23207794
Liver Cancer. 2022 Feb 22;11(4):329-340
pubmed: 35978601
Lancet Oncol. 2014 Oct;15(11):e493-503
pubmed: 25281468
Nat Rev Clin Oncol. 2023 Apr;20(4):250-264
pubmed: 36806788